Intracoronary cardiosphere-derived cell secretome therapy: effects on ventricular tachycardia inducibility and cardiac function in a swine model

Abstract

Listen

Translate article

Abstract Introduction Following myocardial infarction (MI), there is a high risk of sudden cardiac death due to the development of ventricular tachycardia (VT). This study aimed to evaluate the effects of intracoronary (IC) administration of cardiosphere-derived cell secretome (S-CDCs) on VT inducibility and cardiac function in a porcine model of MI. Methods Fourteen pigs underwent endovascular MI induction. At four weeks, either saline (CON; 5 ml; n=7) or S-CDCs (9.16 mg protein in 5 ml saline; n=7) were blindly administered via the IC route. VT inducibility and magnetic resonance (MR) studies were performed both pre- and four months post-IC therapy, assessing ejection fraction (EF), infarct size (%MI), and indexed end-diastolic and end-systolic volumes (VDFi, VSFi). Results IC therapy was successfully performed in all cases. While VT was inducible in 100% of animals prior to IC therapy, the inducibility rate was lower in the S-CDCs group compared to the CON group at four months (57% versus 100%, p=0.05). Additionally, in the S-CDCs group, EF was higher (35±10% versus 29±10%, p=NS), and ventricular volumes were lower (83±18 ml/m² and 56±20 ml/m² versus 88±29 ml/m² and 64±20 ml/m², p=NS). Furthermore, %MI was significantly reduced in the S-CDCs group (12±3% versus 16±3%, p=0.03). Conclusion IC therapy with S-CDCs appears to reduce post-MI VT development and suggests beneficial effects on cardiac function, including a reduction in %MI, in this swine model.